BBV154

AXP000176.1 · Vaccine

Platform
chimpanzee adenovirus (non-replicating, intranasal)
Targets
SARS-CoV-2 S
Originator
Washington University in St. Louis
Sponsor
Bharat Biotech

Names

NameTypeSource
BBV154preferred name, codecurator, press
iNCOVACCbrandpress
ChAd-SARS-CoV-2-S ambiguouscodepress

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
chimpanzee adenovirus
Replication
non replicating
Modifications
replication-deficient adenoviral vector encoding a pre-fusion stabilised SARS-CoV-2 spike
Transgenes
SARS-CoV-2 spike
Route
intranasal
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
otherIN2022-09conditionaliNCOVACCRestricted use in emergency situation for prevention of COVID-19 in adults (primary course and heterologous booster)source

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05522335Phase III Study of BBV154 Intranasal Vaccine in Healthy VolunteersUnknownPhase 32022-04-162022-07-193160COVID-19 Respiratory Infection
NCT05567471Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster DoseCompletedPhase 32022-02-262022-05-03875COVID-19 Respiratory Infection
NCT05639998BBV152/BBV154 Heterologus Prime-Boost StudyCompletedPhase 22021-09-012022-03-01608Corona Virus Infection
NCT04751682Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19CompletedPhase 12021-03-012021-06-25175SARS-CoV Infection

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 36435633Nasal vaccines: solutions for respiratory infectious diseases.Trends in molecular medicine2023cited by trial NCT05522335
PMID 37596281Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®).NPJ vaccines2023cited by trial NCT05522335

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40269252Effect of heterologous intranasal iNCOVACC® vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial.Communications medicine2025name in title: iNCOVACC
PMID 38337035Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection.Nature immunology2024name in abstract: iNCOVACC
PMID 37205450A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters.bioRxiv : the preprint server for biology2023name in abstract: iNCOVACC
PMID 36569867Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).Frontiers in immunology2022name in title: BBV154
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 39083604Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters.Science advances2024name in title: ChAd-SARS-CoV-2-S

Notes

iNCOVACC: replication-deficient adenovirus-vectored vaccine encoding a pre-fusion stabilised SARS-CoV-2 spike, given as nasal drops. Constructs were designed at Washington University in St. Louis (where the vector is described as a chimpanzee adenovirus, ChAd-SARS-CoV-2-S); the Indian regulator granted restricted use in an emergency situation for adults, announced on 6 September 2022, both as a primary two-dose course and as a heterologous booster. The source read does not name the chimpanzee adenovirus serotype, so the strain cell is left empty.

How to cite

BBV154 (AXP000176.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000176.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.